Stryker Acquires Inari Medical for $4.9 Billion in Stryker Deal
The deal is expected to drive growth in the global thrombectomy device market, which was valued at $2.96 billion in 2024. Stryker's acquisition of Inari Medical is a strategic move to expand its presence in the high-growth peripheral vascular market and strengthen its cardiovascular division, ultimately improving patient outcomes worldwide.
Stryker has acquired Inari Medical, a US-based medical device company, for $4.9 billion, expanding its presence in the high-growth peripheral vascular market and strengthening its cardiovascular division. The acquisition provides Stryker with a range of minimally invasive devices for treating venous thromboembolism, including pulmonary embolism and deep vein thrombosis.
Inari Medical's portfolio includes devices such as FlowTriever, ClotTriever, and LimFlow system, which utilize minimally invasive procedures to remove clots from the body. The acquisition is expected to improve outcomes for patients worldwide and expand Stryker's interventional endovascular portfolio. The global thrombectomy device market is expected to grow at a CAGR of 5.48%, driven by rising rates of peripheral artery diseases worldwide.
The acquisition brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. Stryker will acquire all outstanding shares of Inari common stock for $80 per share, making Inari a wholly owned subsidiary. The deal is expected to strengthen Stryker's position in the overall cardiovascular device market, which is expected to grow due to rising rates of peripheral artery diseases worldwide.
The acquisition of Inari Medical by Stryker is a significant development in the medical device industry, and is expected to have a positive impact on patient outcomes. With its expanded portfolio of minimally invasive devices, Stryker is well-positioned to capitalize on the growing demand for effective treatments for venous thromboembolism.
